Overcoming anti-VEGF therapy resistance through use of PMN-MDSC-derived PyNPase

An abstract of the study by Harada et al overcoming anti-VEGF therapy resistance through use of PMN-MDSC-derived PyNPase, is presented. Some preclinical studies suggested that myeloid-derived suppressor cells (MDSCs) would regulate the tumor refractoriness to anti-vascular endothelial growth factor...

Full description

Saved in:
Bibliographic Details
Published in:European journal of cancer (1990) 2016-12, Vol.69, p.S24-S24
Main Authors: Iwai, T, Harada, Y, Maehara, Y, Yonemitsu, Y
Format: Article
Language:English
Subjects:
Angiogenesis
CD11b antigen
Granulocyte colony-stimulating factor
Hematology, Oncology and Palliative Medicine
Oncology
Suppressor cells
Therapy
Thermal resistance
Tumors
Vascular endothelial growth factor
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:An abstract of the study by Harada et al overcoming anti-VEGF therapy resistance through use of PMN-MDSC-derived PyNPase, is presented. Some preclinical studies suggested that myeloid-derived suppressor cells (MDSCs) would regulate the tumor refractoriness to anti-vascular endothelial growth factor (VEGF) treatment via immune-related and escaping anti-angiogenic mechanisms. Capecitabine-treatment restored inhibition both of tumor angiogenesis and tumor growth under treatment of anti-VEGF antibody, and this effect was partly canceled in tumors implanted in mice deficient both with TP and UP. Furthermore, the results not only further confirmed the essential role of G-CSF and the recruitment of CD11bhigh/Gr-1high PMN-MDSCs as a cause of tumor resistance to anti-VEGF, but also revealed that capecitabine overcome this resistance through elimination of PyNPase-expressing PMN-MDSCs.
ISSN:0959-8049
1879-0852
DOI:10.1016/S0959-8049(16)32653-3